(±)-mevalonolactone

DL-Mevalonolactone-D7 is the deuterated form of DL-Mevalonolactone. DL-Mevalonolactone (T1353) ( (±)-Mevalonolactone; Mevalolactone) represents the δ-lactone form of mevalonic acid and serves as a precursor in the mevalonate pathway. It has the capability to reduce mitochondrial membrane potential (∆Ψm), NAD (P)H content, and the calcium ion (Ca2+) retention capacity in the brain.

DL-Mevalonolactone-d4 ((±)-Mevalonolactone-d4) is a deuterium-labeled form of DL-Mevalonolactone. This compound, also known as (±)-Mevalonolactone or Mevalolactone, is the δ-lactone form of mevalonic acid and serves as a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against myopathy caused by HMGCR mutations and statins. Additionally, it induces inflammatory and oxidative stress responses, reduces mitochondrial membrane potential, and causes mitochondrial swelling.

(±)-Mevalonolactone-4,4,5,5-D4 (Standard) is a reference standard of (±)-Mevalonolactone-4,4,5,5-D4 intended for quantitative analysis, quality control, and related biochemical research applications.

DL-Mevalonolactone, a human endogenous metabolite, is the δ-lactone form of mevalonate, a precursor of the mevalonate pathway. It reduces mitochondrial membrane potential (∆Ψm), Ca2+ retention and NAD(P)H levels in the brain, and also induces mitochondrial swelling.DL-Mevalonolactone induces inflammation and oxidative stress, and reduces mitochondrial membrane potential.

Mevalonolactone is a sesquiterpene lactone known to inhibit calcineurin activity against p-Nitrophenyl phosphate, with an IC50 of 134.29 μM.